AMAnne-Geneviève MarcelinMDVideoHIVEuropean HIV Clinical Forum 2017What is the virological support for reduced drug regimens? | Anne-Geneviève Marcelin, MDView Video
GDPGiovanni Di PerriMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2017One pill a day?: Integration novel delivery systems into routine care- Giovanni Di Perri, MD, PhDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Prospects of immunotherapy for treatment- Michael Lederman, MDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Evolution of bone mineral density and MDRD in HIV-infected patients treated with dolutegravir based regimens: results at 48- weeks- A. D'AvinoView Slideset
MPMiłosz ParczewskiMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2017Clinical case presentation- Miłosz Parczewski, MD, PhDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Serum cystatine as a marker for estimated glomerular filtration rate (eGFR) assessment in HIV-1-infected patients with dolutegravir-based antiretroviral therapy (ART).- R. PalichView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Genetic variability of HIV-2 LTR regions impacts transcriptional activities.- Q. Le HingratView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase.- Dr. Olivier DelelisView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Clinical case presentation- Christina Mussini, MDView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network).- A.G. MarcelinView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2017Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.- D. ArmeniaView Slideset
